Literature DB >> 20351233

Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.

Sabine Eichinger1, Georg Heinze, Lisanne M Jandeck, Paul A Kyrle.   

Abstract

BACKGROUND: Predicting the risk of recurrent venous thromboembolism (VTE) in an individual patient is often not feasible. We aimed to develop a simple risk assessment model that improves prediction of the recurrence risk. METHODS AND
RESULTS: In a prospective cohort study, 929 patients with a first unprovoked VTE were followed up for a median of 43.3 months after discontinuation of anticoagulation. We excluded patients with a strong thrombophilic defect such as a natural inhibitor deficiency, the lupus anticoagulant, and homozygous or combined defects. A total of 176 patients (18.9%) had recurrent VTE. Preselected clinical and laboratory variables (age, sex, location of VTE, body mass index, factor V Leiden, prothrombin G20210A mutation, D-dimer, and in vitro thrombin generation) were analyzed in a Cox proportional hazards model, and those variables that were significantly associated with recurrence were used to compute risk scores. Male sex (hazard ratio versus female sex 1.90, 95% confidence interval 1.31 to 2.75), proximal deep vein thrombosis (hazard ratio versus distal 2.08, 95% confidence interval 1.16 to 3.74), pulmonary embolism (hazard ratio versus distal thrombosis 2.60, 95% confidence interval 1.49 to 4.53), and elevated levels of D-dimer (hazard ratio per doubling 1.27, 95% confidence interval 1.08 to 1.51) were related to a higher recurrence risk. Using these variables, we developed a nomogram that can be used to calculate risk scores and to estimate the cumulative probability of recurrence in an individual patient. The model was cross validated, and patients were assigned to different risk categories based on their risk score. Recurrence rates corresponded well with the different risk categories.
CONCLUSIONS: By use of a simple scoring system, the assessment of the recurrence risk in patients with a first unprovoked VTE and without strong thrombophilic defects can be improved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20351233     DOI: 10.1161/CIRCULATIONAHA.109.925214

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  101 in total

Review 1.  Managing pulmonary embolism using prognostic models: future concepts for primary care.

Authors:  Geert-Jan Geersing; Ruud Oudega; Arno W Hoes; Karel G M Moons
Journal:  CMAJ       Date:  2011-12-05       Impact factor: 8.262

2.  Thrombosis: a new scoring system for simple risk prediction in patients with unprovoked venous thromboembolism.

Authors:  Bryony M Mearns
Journal:  Nat Rev Cardiol       Date:  2010-06       Impact factor: 32.419

Review 3.  Predicting the risk of recurrent venous thromboembolism (VTE).

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 4.  Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Authors:  Marc Alan Rodger; Gregoire Le Gal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 5.  Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.

Authors:  Geoffrey D Barnes; Yogendra Kanthi; James B Froehlich
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

6.  [Treatment of deep vein thrombosis and pulmonary embolism].

Authors:  S M Schellong
Journal:  Internist (Berl)       Date:  2011-11       Impact factor: 0.743

7.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

8.  Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism.

Authors:  Ashfaque A Memon; Kristina Sundquist; Xiao Wang; Peter J Svensson; Jan Sundquist; Bengt Zöller
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

Review 9.  Role of thrombophilia testing: con.

Authors:  Scott M Stevens
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 10.  The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal.

Authors:  James Demetrios Douketis
Journal:  Intern Emerg Med       Date:  2016-10-20       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.